The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Welcome to The Cutaneous T-Cell Lymphoma (CTCL) Channel

VJHemOnc brings you important developments in the field of CTCL presented by esteemed experts from around the world. The CTCL Channel offers exclusive video interviews as well as podcasts and in-depth roundtable discussions so you can keep up with the latest wherever you are.

The CTCL Channel covers all key research areas including insightful views on managing Sézary syndrome, systemic therapies including antibody-drug conjugates, novel clinical trial data, and much more.

1:01

Investigating novel therapeutic approaches for T-cell lymphoma

Yumeng Zhang • 8 Dec 2025

$Durvalumab plus lenalidomide versus single-agent durvalumab for refractory/advanced CTCL$ 2:38

Durvalumab plus lenalidomide versus single-agent durvalumab for refractory/advanced CTCL

Christiane Querfeld • 20 Jun 2025

1:38

DR-01, an anti-CD94 monoclonal antibody, in the treatment of ultra-rare cytotoxic T-cell lymphomas

Swaminathan Iyer • 9 Dec 2024

5:21

HRQoL in patients with R/R CTCL treated with lacutamab in the TELLOMAK trial

Pierluigi Porcu • 9 Dec 2024

3:46

The current standard of care for CTCL

Pierluigi Porcu • 9 Dec 2024

2:50

Assessing a 4-weekly dosing schedule of mogamulizumab in pts with mycosis fungoides/Sézary syndrome

Christiane Querfeld • 8 Dec 2024

$Phase II trial of durvalumab + lenalidomide vs single-agent durvalumab in refractory/advanced CTCL$ 3:41

Phase II trial of durvalumab + lenalidomide vs single-agent durvalumab in refractory/advanced CTCL

Christiane Querfeld • 8 Dec 2024